As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of rare anaphylactic event following administration of the vaccine.

Immunisation should be postponed in patients with febrile illness or acute infection.

Vaccination is contraindicated in patients with hypersensitivity to the active substances, to any of the excipients and to eggs and/or chicken proteins (which includes ovalbumin ≤1µg/dose), neomycin and polymyxin.

• Enzira® Suspension for Injection, pre-filled syringe Influenza Vaccine (Split Virion, inactivated) may be given at the same time as other vaccines
• Immunisation should be carried out on separate limbs. It should be noted that the adverse reactions may be intensified
• The immunological response may be diminished if the patient is undergoing immunosuppressant treatment

Due to an increased risk of febrile convulsions, the vaccine is not authorised for use in children aged under 5 years.

Side effects commonly reported are administration site conditions (e.g. redness, swelling, or pain), ecchymosis, induration, fever, malaise, shivering, fatigue, headache, sweating, myalgia and arthralgia.

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk. Adverse events should also be reported to Pfizer Medical Information on 01304 616161

Further information on adverse event reporting can be found by clicking here.

Summary of Product Characteristics can be found on electronic Medicines Compendium (eMC) click here to view.

Patient information Leaflet can be found on electronic Medicines Compendium (eMC) click here to view and download.